Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.

Abstract

Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, Ellipta. Regrettably, there are no head-to-head trials that have shown superiority in the safety or efficacy of FF versus other ICSs, but evidence shows that VI has a quicker onset of effect versus salmeterol. However, the clinical utility of this effect in a maintenance medication is still questionable. Furthermore, benefits of FF/VI over twice-daily ICS/LABA comparator have not been shown yet and, in addition, its adverse event profile is generally consistent with the known class effects of an ICS/LABA fixed dose combination. In particular, there is an increase in the risk of pneumonia among patients treated with FF/VI relative to VI, mainly among those who benefit most from FF/VI. Nevertheless, the interesting pharmacological profiles of both FF and VI, the possibility that FF/VI can be administered once-daily, and the attractive characteristics of Ellipta are important features that could help FF/VI to be a successful combination in the treatment of chronic obstructive pulmonary disease.

• Authors: Maria Gabriella Matera, Annalisa Capuano, Mario Cazzola
• Journal: Expert review of respiratory medicine (Expert Rev Respir Med) Vol. 9 Issue 1 Pg. 5-12 (Feb 2015) ISSN: 1747-6356 [Electronic] England
• PMID: 25482512 (Publication Type: Journal Article, Review)

Chemical References

• Adrenergic beta-2 Receptor Agonists
• Androstadienes
• Benzyl Alcohols
• Bronchodilator Agents
• Chlorobenzenes
• Drug Combinations
• Glucocorticoids
• Powders
• vilanterol
• fluticasone furoate

Topics

• Administration, Inhalation
• Adrenergic beta-2 Receptor Agonists (administration & dosage, adverse effects)
• Androstadienes (administration & dosage, adverse effects)
• Animals
• Benzyl Alcohols (administration & dosage, adverse effects)
• Bronchodilator Agents (administration & dosage)
• Chlorobenzenes (administration & dosage, adverse effects)
• Drug Administration Schedule
• Drug Combinations
• Dry Powder Inhalers
• Glucocorticoids (administration & dosage, adverse effects)
• Humans
• Lung (drug effects, physiopathology)
• Powders
• Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy, physiopathology)
• Treatment Outcome